Protalix BioTherapeutics
PLX
PLX
30 hedge funds and large institutions have $1.3M invested in Protalix BioTherapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Holders
30
Holding in Top 10
–
Calls
$1.63M
Puts
$218K
Top Buyers
| 1 | +$142K | |
| 2 | +$112K | |
| 3 | +$65K | |
| 4 |
Two Sigma Investments
New York
|
+$28K |
| 5 |
CPA
Capital Performance Advisors
Walnut Creek,
California
|
+$28K |
Top Sellers
| 1 | -$259K | |
| 2 | -$67.1K | |
| 3 | -$35K | |
| 4 |
Morgan Stanley
New York
|
-$17.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |